Acute kidney injury (AKI) or acute kidney failure is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. The most common factors associated with higher risk of AKI include hospitalization, especially in intensive care units, old age, peripheral artery disease, diabetes, kidney diseases, high blood pressure, liver diseases, and heart failure. Some of the symptoms that a patient may experience, as the disease progresses, include nausea and vomiting, confusion, dehydration, abdominal pain, rise in blood pressure, mild back pain, and accumulation of fluid in the body (edema).
Acute Kidney Injury (AKI) Therapeutics Under Development (2018)
A majority of drug candidates in the AKI therapeutics pipeline are being administered by the intravenous route, that shows high bioavailability than any other routes of administration. Also, more funding from various health organizations are driving the AKI therapeutics pipeline growth. Further, there are not any drug candidates approved for the treatment of AKI. The lack of any approved medication for the treatment of AKI in the market means that whosoever gets their pipeline drug in the market first, would receive first mover advantage.
As of May 2018, the AKI therapeutics pipeline comprises of 40 drug candidates in different stages of development. The AKI therapeutics pipeline comprises of more number of small molecules, biologicals, and others drug candidates that are developed as peptides and protein.
Apart from trials for drug-based therapeutics for AKI, the ongoing trials for various medical devices, minimally invasive therapy, regenerative medicine, tissue engineering, patient care technology around intensive care, monitoring, and various diagnostic tools for early diagnosis of AKI, are also covered in the report.
Some of the key players involved in the development of AKI therapeutics include Alloksys Life Sciences B.V., Stealth BioTherapeutics Inc., and Angion Biomedica Corp.